. 2015 Jun 25;8:287–294. doi: 10.2147/DMSO.S69282

Table 1.

Comparison of efficacy endpoints

Study	Design	Subjects (n)	Duration (weeks)	Outcomes	Results
Study	Design	Subjects (n)	Duration (weeks)	Outcomes	Cana 100 mg	Cana 300 mg	Placebo
Cana Mono¹⁷	RC, DB, PC	584	26	HbA_1c (%)	−0.77^a	−1.03^a	0.14
				FPG (mmol/L)	−1.5^a	−1.9^a	0.5
				Weight (kg)	−2.5^a	−3.4^a	−0.5
				SBP (mmHg)	−3.7	−5.4	0.4
					Cana 100 mg	Cana 300 mg	Glimepiride

Cana vs SU¹⁸	RC, DB, AC, NI	1,450	52	HbA_1c (%)	−0.82	−0.93^b	−0.81
				FPG (mmol/L)	−1.35	−1.52	−1.02
				Weight (kg)	−3.7^c	−4.0^c	0.7
				SBP (mmHg)	−3.3^c	−4.8^c	0.2
					Cana 100 mg	Cana 300 mg	Sita 100 mg

Cana vs Sita¹⁹	RC, DB, AC, PG, NI	1,284	52	HbA_1c (%)	−0.73	−0.88^d	−0.73
				FPG (mmol/L)	−1.5^d	−2.0^d	−1.0
				Weight (kg)	−3.3^d	−3.7^d	−1.2
				SBP (mmHg)	−3.5^d	−4.7^d	−0.7

Notes:

P<0.05 when compared to placebo;

met pre-specified superiority margins;

P<0.05 when compared to glimepiride;

P<0.05 when compared to sitagliptin.

Abbreviations: Cana, canagliflozin; Mono, monotherapy; RC, randomized controlled; DB, double-blind; PC, placebo controlled; FPG, fasting plasma glucose; SBP, systolic blood pressure; SU, sulfonylurea; AC, active control; NI, non-inferiority trial; Sita, sitagliptin; PG, parallel crossover group.